8,570
+0.23%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Komipharm International Co
Its shares trade on KOSDAQ under the ticker 041960.KQ. It has been listed since 30 October 2001. In the fiscal year to 31 December 2025, it reported revenue of ₩52.47bn and a net loss of ₩7.21bn. At that date it held total assets of ₩133.92bn and shareholders' equity of ₩69.54bn.
Komipharm International Co., Ltd. engages in the development and manufacturing of natural food additives, veterinary vaccines and pharmaceuticals. The company is headquartered in Siheung, Gyeonggi-Do. The company went IPO on 2001-10-30. The Company’s main products include veterinary vaccines such as total vaccines of respiratory disease for swine, vaccines of anthrax disease and black leg for cattle, vaccines for infectious bronchitis and Newcastle disease, and canine respiratory infection killed vaccines, and veterinary pharmaceuticals such as antibiotics, nutrients, disinfectants and others, which are used to treat pneumonia, pasteurellosis, enteritis, mastitis, swine erysipelas, septicemia, leptospirosis and bacterial diseases for livestock. The firm also engages in research and development of anticancer drugs and cancer pain-relieving agents. In addition, the Company provides services such as pathological biopsies, serum tests, and bacteria tests.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 30 Oct 2001
- Website
- komipharm.com ↗
Leadership
Pay as last reported
- Yong Jin YangChairman of the Board, Co-Chief Executive Officer, since 2007
- Seong Cheol MoonPresident, Co-Chief Executive Officer, Director
- Sang Hyeon KimManaging Director, since 2013
- Yi Geun ParkInternal Auditor
- Ms. Su Jeong KimDirector
- Jeong Gi YooNon-Executive Independent Director
- Mi Ran ParkIR Contact Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Komipharm develops natural food additives and veterinary vaccines for livestock health.
- Komipharm manufactures antibiotics and disinfectants for treating bacterial diseases in animals.
- Komipharm focuses on R&D for anticancer drugs and cancer pain-relieving agents.
Weaknesses
- Komipharm's main products are limited to veterinary vaccines and pharmaceuticals.
- Komipharm's R&D for anticancer drugs is still in progress.
- Komipharm's services include pathological biopsies and serum tests.
Opportunities
- Komipharm can expand its veterinary vaccine offerings for swine respiratory diseases.
- Komipharm can grow its market in South Korea's veterinary pharmaceutical sector.
- Komipharm can increase its R&D investment for anticancer drugs.
Threats
- Komipharm faces competition from other veterinary vaccine manufacturers in South Korea.
- Komipharm's reliance on veterinary pharmaceuticals may limit its market diversification.
- Komipharm's anticancer drug R&D could face regulatory challenges in South Korea.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.